These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24393016)

  • 1. Cangrelor: an emerging therapeutic option for patients with coronary artery disease.
    Kubica J; Kozinski M; Navarese EP; Tantry U; Kubica A; Siller-Matula JM; Jeong YH; Fabiszak T; Andruszkiewicz A; Gurbel PA
    Curr Med Res Opin; 2014 May; 30(5):813-28. PubMed ID: 24393016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of data on cangrelor.
    Qamar A; Bhatt DL
    Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.
    Schneider DJ
    Coron Artery Dis; 2016 Jan; 27(1):65-9. PubMed ID: 26444255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cangrelor in clinical use.
    Feng KY; Mahaffey KW
    Future Cardiol; 2020 Mar; 16(2):89-102. PubMed ID: 32067479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cangrelor for treatment during percutaneous coronary intervention.
    Oestreich JH; Dobesh PP
    Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cangrelor for the treatment of patients with Arterial Thrombosis.
    Tantry U; Chaudhary R; Kubica J; Bliden K; Gurbel PA
    Expert Opin Pharmacother; 2018 Aug; 19(12):1389-1398. PubMed ID: 30102083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
    Judge HM; Buckland RJ; Jakubowski JA; Storey RF
    Platelets; 2016; 27(3):191-5. PubMed ID: 26270719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Alexopoulos D; Pappas C; Sfantou D; Lekakis J
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.
    White HD; Chew DP; Dauerman HL; Mahaffey KW; Gibson CM; Stone GW; Gruberg L; Harrington RA; Bhatt DL
    Am Heart J; 2012 Feb; 163(2):182-90.e4. PubMed ID: 22305835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cangrelor: a review on pharmacology and clinical trial development.
    Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cangrelor: a review on its mechanism of action and clinical development.
    Ferreiro JL; Ueno M; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Oct; 7(10):1195-201. PubMed ID: 19814662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging P2Y12 receptor antagonists: role in coronary artery disease.
    Oliphant CS; Doby JB; Blade CL; Das K; Mukherjee D; Das P
    Curr Vasc Pharmacol; 2010 Jan; 8(1):93-101. PubMed ID: 19485932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Expert Opin Drug Saf; 2016; 15(2):275-85. PubMed ID: 26680584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
    Tamborini Permunian E; Riva N; Guasti L; Squizzato A
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):625-37. PubMed ID: 25728292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.
    Marcano AL; Ferreiro JL
    Curr Atheroscler Rep; 2016 Nov; 18(11):66. PubMed ID: 27714642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).
    Marino M; Rizzotti D; Leonardi S
    Curr Cardiol Rep; 2014; 16(6):493. PubMed ID: 24879371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cangrelor for treatment of arterial thrombosis.
    Walsh JA; Price MJ
    Expert Opin Pharmacother; 2014 Mar; 15(4):565-72. PubMed ID: 24479981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of platelet inhibition with cangrelor during PCI on ischemic events.
    Bhatt DL; Stone GW; Mahaffey KW; Gibson CM; Steg PG; Hamm CW; Price MJ; Leonardi S; Gallup D; Bramucci E; Radke PW; Widimský P; Tousek F; Tauth J; Spriggs D; McLaurin BT; Angiolillo DJ; Généreux P; Liu T; Prats J; Todd M; Skerjanec S; White HD; Harrington RA;
    N Engl J Med; 2013 Apr; 368(14):1303-13. PubMed ID: 23473369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.